Array
(
[id] => 2132
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2132.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:41
[updatetime] => 2024-12-19 09:42:41
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => Pre-operative initiation of beta-blockers in advance of high-risk NCS may be considered in patients who have two or more clinical risk factors, in order to reduce the incidence of peri-operative myocardial infarction. (Evidence: Level A，Recommendation: Class IIb )
[laiyuan] => 具有两种或两种以上临床风险因素的患者在行高风险非心脏手术之前可以考虑使用β受体阻滞剂，以降低围手术期心肌梗塞的发生率。（证据等级：A；推荐强度：IIb）
[znzldj] => A
[_inputtime] => 1734572561
[_updatetime] => 1734572561
[_nrjc] =>
[_nrsh] =>
)
推荐意见
具有两种或两种以上临床风险因素的患者在行高风险非心脏手术之前可以考虑使用β受体阻滞剂，以降低围手术期心肌梗塞的发生率。（证据等级：A；推荐强度：IIb）
Pre-operative initiation of beta-blockers in advance of high-risk NCS may be considered in patients who have two or more clinical risk factors, in order to reduce the incidence of peri-operative myocardial infarction. (Evidence: Level A，Recommendation: Class IIb )
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2133
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2133.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:41
[updatetime] => 2024-12-19 09:42:41
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => Pre-operative initiation of beta-blocker in advance of NCS may be considered in patients who have known CAD or myocardial ischaemia. (Evidence: Level B，Recommendation: Class IIb )
[laiyuan] => 患有冠状动脉疾病或心肌缺血的患者在非心脏手术之前可以考虑使用β受体阻滞剂。（证据等级：B；推荐强度：IIb）
[znzldj] => A
[_inputtime] => 1734572561
[_updatetime] => 1734572561
[_nrjc] =>
[_nrsh] =>
)
推荐意见
患有冠状动脉疾病或心肌缺血的患者在非心脏手术之前可以考虑使用β受体阻滞剂。（证据等级：B；推荐强度：IIb）
Pre-operative initiation of beta-blocker in advance of NCS may be considered in patients who have known CAD or myocardial ischaemia. (Evidence: Level B，Recommendation: Class IIb )
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2134
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2134.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:41
[updatetime] => 2024-12-19 09:42:41
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => Routine initiation of beta-blocker peri-operatively is not recommended.(Evidence: Level A，Recommendation: Class III )
[laiyuan] => 不建议围手术期常规使用β受体阻滞剂。（证据等级：A；推荐强度：III）
[znzldj] => A
[_inputtime] => 1734572561
[_updatetime] => 1734572561
[_nrjc] =>
[_nrsh] =>
)
推荐意见
不建议围手术期常规使用β受体阻滞剂。（证据等级：A；推荐强度：III）
Routine initiation of beta-blocker peri-operatively is not recommended.(Evidence: Level A，Recommendation: Class III )
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2135
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2135.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:41
[updatetime] => 2024-12-19 09:42:41
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => Peri-operative continuation of beta-blockers is recommended in patients currently receiving this medication.(Evidence: Level B，Recommendation: Class I)
[laiyuan] => 建议长期使用β受体阻滞剂的患者在围手术期应继续使用。（证据等级：B；推荐强度：I）
[znzldj] => A
[_inputtime] => 1734572561
[_updatetime] => 1734572561
[_nrjc] =>
[_nrsh] =>
)
推荐意见
建议长期使用β受体阻滞剂的患者在围手术期应继续使用。（证据等级：B；推荐强度：I）
Peri-operative continuation of beta-blockers is recommended in patients currently receiving this medication.(Evidence: Level B，Recommendation: Class I)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2136
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2136.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:41
[updatetime] => 2024-12-19 09:42:41
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => In patients already on statins, it is recommended to continue statins during the peri-operative period.(Evidence: Level B，Recommendation: Class I)
[laiyuan] => 术前已经使用他汀类药物的患者，建议在围手术期继续使用。（证据等级：B；推荐强度：I）
[znzldj] => A
[_inputtime] => 1734572561
[_updatetime] => 1734572561
[_nrjc] =>
[_nrsh] =>
)
推荐意见
术前已经使用他汀类药物的患者，建议在围手术期继续使用。（证据等级：B；推荐强度：I）
In patients already on statins, it is recommended to continue statins during the peri-operative period.(Evidence: Level B，Recommendation: Class I)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2137
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2137.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:41
[updatetime] => 2024-12-19 09:42:41
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => In patients with stable HF, peri-operative continuation of RAAS inhibitors may be considered.(Evidence: Level C ，Recommendation: Class IIb)
[laiyuan] => 对于稳定的心力衰竭患者，可以考虑围手术期继续使用RAAS（肾素-血管紧张素-醛固酮系统）抑制剂。（证据等级：C；推荐强度：IIb）
[znzldj] => A
[_inputtime] => 1734572561
[_updatetime] => 1734572561
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于稳定的心力衰竭患者，可以考虑围手术期继续使用RAAS（肾素-血管紧张素-醛固酮系统）抑制剂。（证据等级：C；推荐强度：IIb）
In patients with stable HF, peri-operative continuation of RAAS inhibitors may be considered.(Evidence: Level C ，Recommendation: Class IIb)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2138
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2138.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:41
[updatetime] => 2024-12-19 09:42:41
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => In patients without HF, withholding RAAS inhibitors on the day of NCS should be considered to prevent peri-operative hypotension.(Evidence: Level B，Recommendation: Class IIa)
[laiyuan] => 对于没有心力衰竭的患者，在非心脏手术当天应暂停使用RAAS（肾素-血管紧张素-醛固酮系统）抑制剂，以防止围手术期低血压。（证据等级：B；推荐强度：IIa）
[znzldj] => A
[_inputtime] => 1734572561
[_updatetime] => 1734572561
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于没有心力衰竭的患者，在非心脏手术当天应暂停使用RAAS（肾素-血管紧张素-醛固酮系统）抑制剂，以防止围手术期低血压。（证据等级：B；推荐强度：IIa）
In patients without HF, withholding RAAS inhibitors on the day of NCS should be considered to prevent peri-operative hypotension.(Evidence: Level B，Recommendation: Class IIa)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2139
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2139.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:41
[updatetime] => 2024-12-19 09:42:41
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => For patients on diuretics to treat hypertension,transient discontinuation of diuretics on the day of NCS should be considered.(Evidence: Level B，Recommendation: Class IIa)
[laiyuan] => 对于服用利尿剂治疗高血压的患者，应考虑在非心脏手术当天暂时停用利尿剂。（证据等级：B；推荐强度：IIa）
[znzldj] => A
[_inputtime] => 1734572561
[_updatetime] => 1734572561
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于服用利尿剂治疗高血压的患者，应考虑在非心脏手术当天暂时停用利尿剂。（证据等级：B；推荐强度：IIa）
For patients on diuretics to treat hypertension,transient discontinuation of diuretics on the day of NCS should be considered.(Evidence: Level B，Recommendation: Class IIa)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2140
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2140.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:41
[updatetime] => 2024-12-19 09:42:41
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => It should be considered to interrupt SGLT-2 inhibitor therapy for at least 3 days before intermediate- and high-risk NCS.(Evidence: Level C，Recommendation: Class IIa)
[laiyuan] => 在中高危非心脏手术前，应考虑中断SGLT-2（钠-葡萄糖协同转运蛋白2）抑制剂治疗至少3天。（证据等级：C；推荐强度：IIa）
[znzldj] => A
[_inputtime] => 1734572561
[_updatetime] => 1734572561
[_nrjc] =>
[_nrsh] =>
)
推荐意见
在中高危非心脏手术前，应考虑中断SGLT-2（钠-葡萄糖协同转运蛋白2）抑制剂治疗至少3天。（证据等级：C；推荐强度：IIa）
It should be considered to interrupt SGLT-2 inhibitor therapy for at least 3 days before intermediate- and high-risk NCS.(Evidence: Level C，Recommendation: Class IIa)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2141
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2141.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:41
[updatetime] => 2024-12-19 09:42:41
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => It is recommended to delay elective NCS until 6 months after elective PCI and 12 months after an ACS.(Evidence: Level A ，Recommendation: Class I)
[laiyuan] => 建议将择期非心脏手术延迟至择期经皮冠状动脉介入治疗后6个月和急性冠状动脉综合征后12个月。（证据级别：A；推荐强度：Ⅰ）
[znzldj] => A
[_inputtime] => 1734572561
[_updatetime] => 1734572561
[_nrjc] =>
[_nrsh] =>
)
推荐意见
建议将择期非心脏手术延迟至择期经皮冠状动脉介入治疗后6个月和急性冠状动脉综合征后12个月。（证据级别：A；推荐强度：Ⅰ）
It is recommended to delay elective NCS until 6 months after elective PCI and 12 months after an ACS.(Evidence: Level A ，Recommendation: Class I)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
